SEC EDGARJUN 262 min read$INSM

Lewis William sold $2.2M of INSM

Lewis William (Chair and CEO) sold 21,398 shares of INSMED Inc (INSM) at an average of $103.32 ($102.34–$106.27, $2.21M total) across 5 trades on 2026-06-25 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Lewis William

Published Jun 26, 2026, 4:00 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Aug 6, 2026, 6:57 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$INSM

Neutral

high confidence

Mentioned

$INSM

Relevance

5/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$INSMNeutralLow

Why it matters

The newest disclosed fact is the $2.21M open-market sale executed across five trades on 2026-06-25, under a pre-arranged Rule 10b5-1 plan.

Market read

Traders may note the insider selling as a sentiment datapoint, but the 10b5-1 structure and lack of company-specific news limit trading impact.

What to watch

The article does not disclose any concurrent company-specific catalyst (earnings, trial readout, financing, or regulatory event), so traders should avoid over-weighting the sale versus fundamentals.

Relevance 5/10Novelty 3/10Timing: filed 2026-06-26 after trades on 2026-06-25

Background

This is an SEC Form 4 insider transaction disclosure for INSMED Inc, reported by Lewis William (Chair and CEO).

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$INSMNeutralHigh confidence

Context

INSMED CEO and Chair Lewis William sold about 21,398 shares in open-market trades totaling $2.21M under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect is more sentiment than fundamentals.

Evidence & confidence

The filing is a Form 4 insider transaction and explicitly states a pre-arranged 10b5-1 plan, which typically reduces signaling value versus discretionary sales.

Market effects

Sector

No sector-wide read-through is provided beyond routine insider activity at a single biotech issuer.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Even with a 10b5-1 plan, repeated insider selling can still coincide with internal views on near-term risk, especially if other insiders also sell.

Key entities

issuer
INSMED Inc
US-listed company whose CEO/Chair insider sale is disclosed via Form 4.
insider
Lewis William
Chair and CEO who sold shares totaling $2.21M under a 10b5-1 plan.

Read at source ← All news

OCT 22

$INSMMed

Brensocatib Launches in Japan for Non-CF Bronchiectasis

Insmed Inc. launched Brinsupri (brensocatib hydrate) in Japan for non-cystic fibrosis bronchiectasis, following approvals in the U.S. and Europe. The treatment, backed by clinical trial data, is the first of its kind in Japan. Insmed executives highlighted its potential to address unmet medical needs and improve patient outcomes.

ajmc.com3 min

OCT 20

$INSMLow

Insmed Appoints Former Sanofi CEO Paul Hudson and Utpal Koppikar to Board

Insmed Inc. (INSM) added former Sanofi CEO Paul Hudson and Verily Health CFO Utpal Koppikar to its board, enhancing commercial and financial expertise. The company is expanding globally and advancing its drug pipeline. Hudson and Koppikar bring extensive experience in pharmaceutical operations and financial management, respectively.

citybiz.co2 min

OCT 19

$INSMHigh

Insmed launches bronchiectasis treatment in Japan

Insmed Incorporated (INSM) launched BRINSUPRI Tablets 25 mg in Japan for treating non-cystic fibrosis bronchiectasis in adults and pediatric patients 12+. The therapy, approved in August 2026, is the first of its kind in Japan. BRINSUPRI is also approved in the U.S. and EU for similar indications. Common side effects include rash, dry skin, and hypertension. Insmed is a biopharmaceutical company based in New Jersey.

investing.com1 min

OCT 19

$INSMMed

In Japan, patients can now get the only approved treatment for a lung disease that permanently widens airways.

Insmed Inc. announced that BRINSUPRI, the first approved treatment for non-cystic fibrosis bronchiectasis (NCFB), is now available by prescription in Japan. BRINSUPRI is a once-daily oral therapy designed to reduce airway inflammation. The company highlighted the substantial disease burden of NCFB and the need for effective treatments. Insmed also provided details on the drug's safety profile and potential side effects, including dermatologic and gingival adverse reactions.

stocktitan.net2 min

OCT 15

$INSMMedAI 8/10

Insmed launches four phase 3 trials for lung disease therapy

Insmed Inc. (INSM) launched four Phase 3 trials for its lung disease therapy, treprostinil palmitil. The PALM program includes studies for pulmonary arterial hypertension, pulmonary hypertension with interstitial lung disease, progressive pulmonary fibrosis, and idiopathic pulmonary fibrosis. Three trials have started, with the fourth expected in early 2027. The therapy is not yet approved.

investing.com2 min

OCT 14